Phase 3 Randomized Study Comparing JNJ-79635322 in Combination with Pomalidomide, versus Belanatamab Mafodotin, Pomalidomide and Dexamethasone (BPd) or Daratumumab, Carfilzomib and Dexamethasone (DKd) in Participants with Relapsed or Refractory Multiple Myeloma